There has been extensive coverage about Moderna and its mRNA vaccines lately. Chronic urticaria has been linked to its COVID-19 vaccine and comparative analysis with other vaccines is ongoing. Despite some negative performance in the healthcare stock sector, Moderna has shown surprising profits attributed to its COVID-19 vaccine sales and cost cuts. Moderna has also been granted $176 million by the U.S. government to produce an mRNA bird flu vaccine. Issues of patent infringement with GSK have surfaced and Northwestern University has filed a suit seeking royalties for the vaccine technology used. The company's trial results have been promising, showing early success against solid tumour and norovirus. The Moderna RSV vaccine has been given green light for older adults by the FDA. Despite experiencing a recent sell-off, Moderna maintains an optimistic outlook. Vaccination dosing intervals have been examined for risk factor. Moderna’s focus in cancer research and partnership potentials continue to attract attention. With developments in influenza vaccines and more, the company's profile has highlighted its commitment to revolutionizing the biotech sector.
Moderna MRNA News Analytics from Fri, 01 Mar 2024 08:00:00 GMT to Sun, 01 Dec 2024 00:07:17 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 2
